Light-Activated Protein Phosphatase Operon for Spatiotemporal Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective tools to control, reduce, or enhance the activity of phosphorylation-regulating enzymes in living cells, which is crucial for understanding and treating disorders associated with protein phosphorylation.
Innovation Solution
The construction of genetic operons that produce biologically active agents, such as light-activated protein phosphatases, to control phosphatase function within living cells or identify small molecule inhibitors/activators/modulators of protein phosphatases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If genetic operons are constructed to produce light-activated protein phosphatases, then spatiotemporal control over phosphatase activity is achieved, but device complexity increases
Solution Approach 1:
The genetic operon is divided into multiple functional modules: a light-sensitive domain (LOV2), a phosphatase catalytic domain, a substrate recognition domain (SH2), and a DNA-binding domain (434 cI repressor). Each module performs a specific function, allowing independent optimization and characterization while working together to achieve light-controlled phosphatase activity.
Solution Approach 2:
The patent combines multiple protein domains into fusion proteins: the LOV2 domain is fused to the phosphatase catalytic domain to create light sensitivity, the SH2 domain is fused to the DNA-binding domain to create substrate-specific recruitment, and these fusion proteins are expressed together in the operon system to achieve coordinated function.
2Adaptability or versatility
If fusion proteins with multiple domains are constructed, then specific binding and catalytic functions are integrated, but manufacturing precision requirements increase
Solution Approach 1:
Flexible linker sequences are used as intermediaries between protein domains to ensure proper folding and functional independence of each domain while maintaining the integrity of the fusion protein. The linkers allow domains to move relative to each other, preventing steric hindrance and ensuring each domain can perform its function optimally.
Solution Approach 2:
The patent optimizes various parameters including linker length and composition, domain orientation (N-terminal vs C-terminal fusion), and expression conditions to achieve proper protein folding and function. Different variants of the fusion proteins are tested to determine the optimal configuration for each specific application.
3Measurement precision
If operons with multiple genes are constructed, then comprehensive detection capability is achieved, but ease of manufacture decreases
Solution Approach 1:
The operon is designed with universal components that can be adapted for different applications: the 434 cI repressor and operator system provides a universal DNA-binding mechanism, the LOV2 domain provides universal light sensitivity, and the SH2 domain provides universal phosphotyrosine recognition. These universal elements can be combined with different phosphatase catalytic domains to create variants for different substrates and applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables spatiotemporal control over protein phosphatase activity, facilitating the study of cell signaling mechanisms and the identification of therapeutic targets for diseases related to protein phosphorylation.
Implementation Method 1
a first light-sensitive domain of a first light-oxygen-voltage dimer (LOV2) domain and a C-terminal catalytic domain of a protein phosphatase 1B (PTP1B) enzyme
Data Source
AI summary
This invention relates to the field of genetic engineering. Specifically, the invention relates to the construction of operons to produce biologically active agents. For example, operons may be constructed to produce agents that control the function of biochemical pathway proteins (e.g., protein phosphatases, kinases and/or proteases). Such agents may include inhibitors and modulators that may be used in studying or controlling phosphatase function associated with abnormalities in a phosphatase pathway or expression level. Fusion proteins, such as light activated protein phosphatases, may be genetically encoded and expressed as photoswitchable phosphatases. Systems are provided for use in controlling phosphatase function within living cells or in identifying small molecule inhibitors/activator/modulator molecules of protein phosphatases associated with cell signaling.